Under the deal, health research discoveries made at TODAI will be advanced towards commercialization via CDRD’s drug development infrastructure, professional project management, and scientific and business expertise.
TODAI president and CEO Takafumi Yamamoto said most of the inventions disclosed at the University are pre-commercial technologies that require much further development.
"We believe that this affiliation agreement with CDRD will bring many benefits to the university and researchers to address this gap in the commercialization path," Yamamoto added.
TODAI TLO, which manages all intellectual property from the University of Tokyo, received 648 invention disclosures last year.